HFA
VRTX icon

HC Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

HC Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$12K Buy
+42
New +$11.2K 0.01% 223

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HC Financial Advisors's VRTX Position: Q2 2022 in Review

HC Financial Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2022: 42 shares worth $12K. The stake represents 0.01% of the portfolio and ranks #223 among its holdings.

1,107 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • HC Financial Advisors held 42 shares of Vertex Pharmaceuticals worth $12K as of Q2 2022.
  • Vertex Pharmaceuticals was a new HC Financial Advisors position in Q2 2022.
  • Vertex Pharmaceuticals made up 0.01% of HC Financial Advisors's portfolio in Q2 2022, its #223 holding.
  • 1,107 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on HC Financial Advisors's 13F filing for Q2 2022, filed 25 Jul 2022.